Industry Updates in Advanced Therapy Medicinal Products and Regenerative Medicine – March 2026

The document outlines significant advancements and collaborations in advanced therapy medicinal products and regenerative medicine as of March 2026. Notable developments include a $7.65 million partnership for gene therapy targeting Anoctamin 5-related disease, AI-engineered T cell receptors for cancer treatment, and new product launches like iPSC-derived sensory neurons. Clinical trials reported positive outcomes for therapies targeting Parkinson's disease, cervical cancer, and muscular dystrophy. Regulatory updates highlight EMA's consultation on microbiome-based therapies and the approval of several therapies, including a regenerative approach to androgenetic alopecia. These updates reflect ongoing progress and investment in the field.